ArticleInternational journal of cardiology. Heart & vasculature2025
Hemoglobin is associated with cardiotoxicity in melanoma patients without anemia receiving immune checkpoint inhibitor therapy.
Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hematological Toxicities in the Modern Era of Melanoma Therapy.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Low hemoglobin values are associated with cardiotoxicity in patients with melanoma and other cancer entities receiving immune checkpoint inhibitor (ICI) therapy. However, in cancer patients under chemotherapy, enhanced incidence of cardiotoxicity events are also reported with increasing hemoglobin values. So far, the association between hemoglobin values within the normal limits and the incidence of cardiotoxicity in melanoma patients treated with ICI therapy has not been examined. Methods: We analyzed 114 melanoma patients receiving ICI therapy (61 ± 13 years; 38 % female) from the prospective Essen Cardio-Oncology Registry (EcoR). Patients with cancer-related anemia (hemoglobin < 11 g/dL) were excluded from the analysis. Baseline hemoglobin levels were assessed at patient enrollment before initiation of ICI therapy. Endpoint was the whole spectrum of cancer therapy-related cardiovascular toxicity (CTR-CVT) according to the European guidelines on cardio-oncology with a median follow-up of 464 days. Results: Hemoglobin values and overall CTR-CVT were positively associated with hazard ratio (HR) rising in a J-shaped curve depending on increasing hemoglobin values. Subgroup analysis revealed only a significant association of hemoglobin and cancer therapy-related cardiac dysfunction (CTRCD) (HR: 1.417; 95 % confidence interval (CI): 1.101 - 1.825; Conclusions: Hemoglobin values within the normal limits are associated with cardiovascular toxicity in terms of CTRCD in this cohort of melanoma patients receiving ICI treatment. Future studies are needed to investigate underlying mechanisms and validate the clinical utility of hemoglobin as a potential additional biomarker for risk stratification in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.